altermune
DESCRIPTION
Altermune. Kary B. Mullis. The α -gal epitope. α -gal is NOT produced in humans, chimps, orangutan or gt -/- mouse A strong anti- α -gal response is already ubiquitous in all humans. The anti-Gal response. 0.1uM IgG 2. Altermune Linker. Aptamer will bind to M2e. alpha-gal epitope. - PowerPoint PPT PresentationTRANSCRIPT
AltermuneKary B. Mullis
The α-gal epitope
• α-gal is NOT produced in humans, chimps, orangutan or gt -/- mouse
• A strong anti-α-gal response is already ubiquitous in all humans
The anti-Gal response
0.1uMIgG2
Altermune Linker
alpha-gal epitopeAptamer willbind to M2e
The Altermune Linker
Spiegelmer StrategyEulberg and Klussmann
ChemBioChem 2003
Altermune linker attaches to pathogen
Altermune linker attracts alpha-Gal antibodies
M2target of amantadine
M2e MSLLTEVET: The Achilles Heel of
influenzais bicistronic
A human to human influenza virion detected
by Altermune
natural killer cell attacks infected cell
Total DNA Linker
Today
Model system with Ab to Phenylarsonateand Haemophilus influenza bacteria in rats.
gt-/- mice
Building linker to hemagglutinin peptide from H3N2
Made M2e peptides
0
25
50
75
100%
Pro
tec
ted
200 100 30 10 3
Fab-Ars Dose
Protection from Hib Bacteremia by Fab-Ars Linker
% Protected: percentage of rats in each treatmentgroup that had sterile blood cultures, i.e. <20 HibCFU/ml.
Protection of Neonatal Rats From Hib Bacteremia by Treatment with Anti-Arsonate Antibodiesand [Fab Anti-HibPS-Arsonate] Linker* Group Anti-Ars Fab41-Ars Hib CFU/ml of Blood† (mg) (g) 1 - - >1 x106, 5.0 x 105
2 0.1 - 5.6 x 105, 5 x 105, 2.7 x 105, 1.5 x 105, 1.0 x 105, 6.9 x 104
3 - 200 4.0 x 105, 7.0 x 104, 6.0 x 104
4 - 100 >1 x 106, 2.5 x 105, 1.7 x 105, 1.0 x 105
5 - 30 1.0 x 105, 1.0 x 105, 4.0 x 104, 2.0 x 104
6 - 10 1.6 x 105, 9.0 x 104, 6.0 x 104, 1.0 x 104
7 - 3 >1 x 106, 2.6 x 105, 9.0 x 104, 3.0 x 104
8 - 1 >1 x 106, >1 x106, 6.4 x 105, 1.7 x 105
9 - 0.3 >1 x 106, >1 x 106, 7.0 x 104, 4.0 x 104
10 - 0.1 >1 x 106, 4.1 x 105, 1.8 x 105, 1.5 x 105
11 0.1 200 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20
12 0.1 100 1.4 x 103, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20
13 0.1 30 1.2 x 105, 1.2 x 104, 2.5 x 103, 2.2 x 103, 2.2 x 103, <20, <20, <20, <20, <20, <20,
14 0.1 10 1.1 x 105, 2.8 x 104, 2.7 x 104, 1.3 x 104, 9.8 x 103, 6.2 x 103, 4.9 x 103, 2.4 x 103, 2.4 x 103, <20, <20
15 0.1 3 >1 x 106, 6.4 x 105, 1.8 x 105, 1.1 x 105, 5.1 x 104, 2.5 x 104, 1.7 x 104, 4.6 x 103, 4.6 x 103, 4.3 x 103, 2.3 x 103
16 0.1 1 >1 x 106, 2.0 x 105, 1.9 x 105, 1.3 x 105, 2.8 x 104, 2.5 x 104, 2.4 x 104, 8.7 x 103, 7.5 x 103, 1.9 x 103
17 0.1 0.3 >1 x 106, 6.2 x 105, 5.4 x 105, 4.5 x 105, 3.0 x 105, 7.5 x 104, 6.3 x 104, 5.2 x 104, 2.1 x 104, 1.3 x 104, 1.6 x 103
18 0.1 0.1 >1 x 106, 4.0 x 105, 3.2 x 105, 2.1 x 105, 2.1 x 105, 2.0 x 105, 2.0 x 105, 1.4 x 105, 1.1 x 105, 1.0 x 105, 1.4 x 104
O
O
O
OHOH
HOOH OH
OH
OO
OH
HO
NHAc
OH O NH
O
POO
OHO
AATTGAATAAGCTGGTATGTTGGTCACATAACGCCAACGCCAAAACTCTGAGTCGGGAAATCACTCCCAATTA
OO
N3 +
CuSO4, sodium ascorbate
10
O
OO
HO HO
OHHOHO
HO
O O
HO
OH
AcHN
HOO
O
POO
OHO
AATTGAATAAGCTGGTATGTTGGTCACATAACGCCAACGCCAAAACTCTGAGTCGGGAAATCACTCCCAATTA
OO
N
NN
13
14
Aptamer binds to 161 aa peptide from H3N2 hemagglutinin
Ruth Arnon, JBC 279, 2004
Appendix A Reduction of infectivity in vitro of influenza virus on chicken cells by Altermune linker (apt-gal).
1.00E+07
1.10E+08
2.10E+08
3.10E+08
4.10E+08
5.10E+08
6.10E+08
7.10E+08
8.10E+08
TC
ID50
Mean virus titers 4.63E+08 1.27E+08 9.67E+07 6.13E+07 5.73E+07
cntrl 1uM apt 0.2 uM apt 1 uM apt-gal 0.2 uM apt-gal
Appendix B
Degradation of Lethal Factor Aptamer Cocktail or Protective Antigen Cocktail, Unmodified (UN) versus Modified (PEG or
Phosphorothioate) Under Varying Conditions
CTRL 5 min. 15 min. 30 min.
UN PEG UN PEG UN PEG UN PEG
Nuclease
CTRL 1h 2h 4h 6h
UN PEG UN PEG UN PEG UN PEG UN PEG
70% FBS 70% FBS
CTRL 2h 4h 6h 24h
UN Th UN Th UN Th UN Th UN Th
UN Th UN Th UN Th UN Th UN Th
CTRL 1h 4h 6h 24h
Nuclease
UN=UnmodifiedPEG=PEG-modifiedTh=Phosphorothioate modified
Survival Curve of A/J Mice Immunized with Human Serum, Challenged
with BAS and Treated with α-gal PAA-12 Aptamer and Doxycycline
•A/J mice were immunized intraperitoneally with either 1X PBS or 1% human serum 1X per week for 5 weeks.
•Mice were challenged intranasally with either 1X PBS or 1X106 BAS (Sterne strain).
•Mice were treated with either PBS (with or without human serum) or PAA-12 aptamer drug ( 75 ug /dose with human serum) at 2 hours following challenge and every 24 hours thereafter for 10 days and either PBS or doxycycline (1.5 mg/kg – mouse dose) at 12 or 24 hours following challenge and for every 24 hours thereafter for 14 days:
•Survival was monitored daily for 28 days.
The Future:Priming the immune system
for specific diversion by Altermune
A set of immunogens is chosen for:
•Convenient synthesis
•Safety
•The distinct spectrum of immune responses provoked
Various immunogens with their resultant immune responses
M13 Filamentous Phage
Collaborators• Dr. Alex Lucas, Childrens’ Hospital of Oakland
Research Institute, Oakland, CA
• Dr. Rick Lyons, University of New Mexico, Albuquerque
• Dr. Ron Cook, Biosearch, Novato, CA
• Dr. Carol Cardona, UC Davis, CA
• Dr. Jeeva Vivikananda, Dr. Jonathan Kiel, Brooks Air Force Base, San Antonio, TX
supported by DARPA